「エプスタイン・バール・ウイルス」の版間の差分

EBVに有効なワクチンは今のところ存在しない<ref group="注釈" name=":1810">Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M (2007).&nbsp;[https://www.ncbi.nlm.nih.gov/pubmed/18190254 “Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults”].&nbsp;''The Journal of Infectious Diseases''. '''196'''&nbsp;(12): 1749–53.,&nbsp;[[PubMed|PMID]]&nbsp;[https://www.ncbi.nlm.nih.gov/pubmed/18190254 18190254], [[デジタルオブジェクト識別子|doi]]: [https://academic.oup.com/jid/article/196/12/1749/892441 10.1086/523813].</ref>。EBVに有効な抗ウイルス剤の[[ソリブジン]]・[[ブリブジン]]は存在するが、ソリブジンと抗がん剤[[5-FU]]の併用によって起きた薬害事故の影響で、日本においては使用不可能な状態にある<ref name=":20" /><ref name=":21" />。

EBVに対する[[ワクチン]]は今の所できていない<ref name=":1810" group="注釈" />。2006年から2008年にかけて何回かの臨床試験が行われていた<ref>{{Cite journal|last=Crawford|first=Dorothy H.|last2=Macsween|first2=Karen F.|last3=Higgins|first3=Craig D.|last4=Thomas|first4=Ranjit|last5=McAulay|first5=Karen|last6=Williams|first6=Hilary|last7=Harrison|first7=Nadine|last8=Reid|first8=Stuart|last9=Conacher|first9=Margaret|date=2006-08-01|title=A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis|url=https://www.ncbi.nlm.nih.gov/pubmed/16804839|journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America|volume=43|issue=3|pages=276–282|doi=10.1086/505400|issn=1537-6591|pmid=16804839}}</ref><ref>{{Cite journal|last=Elliott|first=Suzanne L.|last2=Suhrbier|first2=Andreas|last3=Miles|first3=John J.|last4=Lawrence|first4=Greg|last5=Pye|first5=Stephanie J.|last6=Le|first6=Thuy T.|last7=Rosenstengel|first7=Andrew|last8=Nguyen|first8=Tam|last9=Allworth|first9=Anthony|date=2008-2|title=Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis|url=https://www.ncbi.nlm.nih.gov/pubmed/18032491|journal=Journal of Virology|volume=82|issue=3|pages=1448–1457|doi=10.1128/JVI.01409-07|issn=1098-5514|pmid=18032491|pmc=PMC2224445}}</ref><ref name=":19">{{Cite journal|last=Moutschen|first=Michel|last2=Léonard|first2=Philippe|last3=Sokal|first3=Etienne M.|last4=Smets|first4=Françoise|last5=Haumont|first5=Michèle|last6=Mazzu|first6=Pasqualina|last7=Bollen|first7=Alex|last8=Denamur|first8=Francoise|last9=Peeters|first9=Pascal|date=2007-06-11|title=Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults|url=https://www.ncbi.nlm.nih.gov/pubmed/17485150|journal=Vaccine|volume=25|issue=24|pages=4697–4705|doi=10.1016/j.vaccine.2007.04.008|issn=0264-410X|pmid=17485150}}</ref>。EBVのgp350などがワクチンの標的として支持されてきた<ref name=":19" /><ref>{{Cite journal|last=Taylor|first=G. S.|last2=Haigh|first2=T. A.|last3=Gudgeon|first3=N. H.|last4=Phelps|first4=R. J.|last5=Lee|first5=S. P.|last6=Steven|first6=N. M.|last7=Rickinson|first7=A. B.|date=2004-1|title=Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma|url=https://www.ncbi.nlm.nih.gov/pubmed/14694109|journal=Journal of Virology|volume=78|issue=2|pages=768–778|doi=10.1128/JVI.78.2.768-778.2004|issn=0022-538X|pmid=14694109|pmc=PMC368843}}</ref>。また、EBVのウイルス様粒子（virus-like particle；VLP）を用いたEBVワクチンの開発が活発に行われている<ref>{{Cite journal|last=Shumilov|first=Anatoliy|last2=Tsai|first2=Ming-Han|last3=Schlosser|first3=Yvonne T.|last4=Kratz|first4=Anne-Sophie|last5=Bernhardt|first5=Katharina|last6=Fink|first6=Susanne|last7=Mizani|first7=Tuba|last8=Lin|first8=Xiaochen|last9=Jauch|first9=Anna|date=2017-02-10|title=Epstein-Barr virus particles induce centrosome amplification and chromosomal instability|url=https://www.ncbi.nlm.nih.gov/pubmed/28186092|journal=Nature Communications|volume=8|pages=14257|doi=10.1038/ncomms14257|issn=2041-1723|pmid=28186092|pmc=PMC5309802}}</ref>。